NASDAQ:GERNGeron Stock Price, Forecast & News

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 56.3% and is now trading at $1.61. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron.

Geron Co. (NASDAQ:GERN) posted its quarterly earnings data on Thursday, May, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.04. Geron had a negative return on equity of 44.66% and a negative net margin of 14,901.74%. During the same period in the previous year, the company posted ($0.05) earnings per share. View Geron's earnings history.

5 brokerages have issued 12-month price objectives for Geron's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Geron's stock price to reach $3.60 in the next year. This suggests a possible upside of 123.6% from the stock's current price. View analysts' price targets for Geron.

News stories about GERN stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the next few days. View the latest news aboutGeron.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Amarin (AMRN), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Dynavax Technologies (DVAX), Anavex Life Sciences (AVXL), Puma Biotechnology (PBYI), Advanced Micro Devices (AMD) and Chesapeake Energy (CHK).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.82%), State Street Corp (1.86%), Geode Capital Management LLC (1.37%), Two Sigma Investments LP (0.80%), Bank of New York Mellon Corp (0.42%) and Two Sigma Advisers LP (0.33%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View institutional ownership trends for Geron.

GERN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, SG Americas Securities LLC, Virtus ETF Advisers LLC, Creative Planning, and Deutsche Bank AG. View insider buying and selling activity for Geron.

GERN stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Geode Capital Management LLC, Invesco Ltd., State Street Corp, BlackRock Inc., Advisor Group Holdings Inc., and Commonwealth Equity Services LLC. View insider buying and selling activity for Geron.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $1.61.

Geron has a market capitalization of $322.58 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

The official website for Geron is www.geron.com.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]